KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. PMID 41860544 · JAMA Neurol · 2026-May-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial. PMID 41860533 · JAMA Neurol · 2026-May-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis. PMID 41817516 · JAMA Otolaryngol Head Neck Surg · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
More Questions Than Answers in Trial of GRAIL's Galleri. PMID 41817436 · Cancer Discov · 2026-May-01 The record describes a randomized, controlled trial of a diagnostic test (Galleri) for early cancer detection, not a therapeutic drug intervention. The primary endpoint is a reduction in late-stage cancers, which is not a time-to-event efficacy endpoint (like OS, PFS, etc.) as required. Phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. PMID 41811339 · JAMA Dermatol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial. PMID 41784985 · JAMA Oncol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). PMID 41738176 · Am J Respir Crit Care Med · 2026-May-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. PMID 41720449 · Cancer Lett · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. PMID 41706486 · JAMA Cardiol · 2026-May-01 This is a randomized, open-label Phase II trial (based on sample size and design, not explicitly Phase III) comparing GnRH agonist vs antagonist in men with prostate cancer. The primary endpoint is change in coronary plaque volume (a surrogate/imaging endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier curves or hazard ratios for time-to-event outcomes are reported. It is a cardiovascular safety/biological study, not a definitive efficacy trial for oncologic endpoints.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase III cardiac rehabilitation improves left ventricular ejection fraction in patients with coronary artery disease and mildly reduced ejection fraction after percutaneous coronary intervention. PMID 41662912 · Int J Cardiol · 2026-May-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Generating the Evidence to Support Stereotactic Radiation Therapy Evolution: Challenges and a Roadmap for Progress. PMID 41651386 · Int J Radiat Oncol Biol Phys · 2026-May-01 The article is a review/commentary on the state of phase III trials in radiation oncology, not an original result report of a randomized trial with a drug intervention and a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA Nephropathy. PMID 41442197 · Kidney360 · 2026-May-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study. PMID 41369302 · Int Clin Psychopharmacol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. PMID 41262042 · Haematologica · 2026-May-01 The record is a randomized, drug-intervention oncology trial with primary time-to-event (PFS, OS) results. However, the provided metadata (title, abstract, publication types, mesh terms) does not explicitly state the trial phase as Phase III, IIIb, or Phase II/III. The criteria require this phase to be explicitly established for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Segment 4b/5 Versus Wedge Resection for Gallbladder Adenocarcinoma: A Randomized Controlled Trial. PMID 40996213 · Ann Surg · 2026-May-01 The report is an eligible Phase III randomized trial with primary time-to-event efficacy endpoints (DFS and OS) in human oncology, but the intervention is purely surgical (liver resection techniques) and does not involve a drug-containing treatment arm, which is a mandatory criterion for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial. PMID 40714135 · Int J Radiat Oncol Biol Phys · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial. PMID 40482729 · Int J Radiat Oncol Biol Phys · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia. PMID 40277212 · Eur J Cancer Prev · 2026-May-01 The record describes a prospective, likely non-randomized comparative study of adjuvant HPV vaccination after conization for cervical dysplasia. While it is oncology-related, human, includes a drug intervention (vaccine), and reports time-to-event outcomes with hazard ratios, it does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial. The study design appears observational (counseled on vaccination, not randomly assigned), and the primary outcome is recurrence of HPV-related lesions/dysplasia, which is a precursor condition rather than a standard oncologic efficacy endpoint. The abstract explicitly notes that ongoing randomized trials are needed for more robust evidence, confirming this is not a definitive trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis. PMID 42394449 · Immunotherapy · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. PMID 42371751 · Curr Med Res Opin · 2026-May The record is an exploratory comparative efficacy analysis (matching-adjusted indirect comparison) synthesizing data from two existing trials (RATIONALE-305 and DisTinGuish). While it reports on randomized Phase III trials and includes a time-to-event endpoint (PFS), it is not itself a primary or original formal-result report of a single Phase III trial; it is a secondary analysis. The deterministic review correctly flagged unclear phase evidence, but the primary exclusion is the report type.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Oral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials. PMID 42344814 · Cureus · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Initial Testing of a Novel, Mental Imagery-Based Anxiety Intervention for People With Mild to Moderate Intellectual Disabilities Using a Single Case Experimental Design. PMID 42307248 · J Appl Res Intellect Disabil · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis. PMID 42281670 · Cureus · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Proton Beam Therapy in Prostate Cancer: Clinical Evidence, Controversies and Future Directions. PMID 42265951 · Arch Esp Urol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bentracimab for Surgical and Perioperative Bleeding: Clinical Efficacy, Emerging Safety Concerns, and Implementation Challenges (Cost, Accessibility, and Evidence Gaps). PMID 42238162 · Cureus · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial. PMID 42215159 · ESMO Open · 2026-May The report is an original, randomized Phase III trial in oncology, but its primary endpoint is the concordance between clinician-reported toxicities and patient-reported symptom severity, not a time-to-event efficacy endpoint like OS, PFS, or DFS. It is therefore excluded as a secondary/safety analysis.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. PMID 42205142 · EClinicalMedicine · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial. PMID 42201929 · PLoS Med · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B Clostridioides difficile Vaccine in Adults 50 Years and Older. PMID 42182836 · Open Forum Infect Dis · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study. PMID 42182073 · J Orthop Translat · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Who Are Insulin-Naïve: Japan Subgroup Analysis of QWINT-2. PMID 42177728 · Diabetes Ther · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa. PMID 42161369 · Int J Urol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study. PMID 42157574 · Eur J Neurol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies. PMID 42152504 · ACR Open Rheumatol · 2026-May The study is not oncology-related (psoriatic arthritis) and does not have a time-to-event efficacy endpoint (OS, PFS, etc.) as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial. PMID 42149110 · Microb Genom · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. PMID 42140261 · J Natl Compr Canc Netw · 2026-May The record is a meta-analysis of RCTs for cancer-related fatigue, not an original trial report. While it discusses phase III data and drug interventions, its primary endpoint is a patient-reported fatigue score (FACIT-F), not a time-to-event efficacy endpoint (e.g., OS, PFS).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial. PMID 42133282 · Dermatol Ther (Heidelb) · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. PMID 42130156 · J Clin Hypertens (Greenwich) · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. PMID 42128580 · J Card Fail · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Real-time electronic drug monitoring: experiences from a multinational phase 3 clinical trial to prevent multidrug-resistant TB. PMID 42125014 · IJTLD Open · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
QT prolongation in participants receiving bedaquiline-containing regimens: analysis of data from Phase 3 STREAM Stage 2. PMID 42125011 · IJTLD Open · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT. PMID 42116552 · Health Technol Assess · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial. PMID 42114035 · JCO Precis Oncol · 2026-May The report is a subgroup/biomarker analysis of a Phase III trial, not a primary, interim, final, or updated efficacy result report. The required primary or key secondary time-to-event efficacy data are not presented in this abstract.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. PMID 42104877 · United European Gastroenterol J · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial. PMID 42104207 · Expert Opin Biol Ther · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The ILEOSTIM trial: A multicentre randomised controlled trial evaluating the impact of efferent loop stimulation prior to ileostomy reversal on postoperative ileus. PMID 42092745 · Colorectal Dis · 2026-May The record is excluded because it lacks a drug-containing intervention (it evaluates a procedural intervention: efferent loop stimulation) and does not have a time-to-event efficacy endpoint (the primary endpoint is the incidence of postoperative ileus, a binary outcome, not OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection. PMID 42085933 · EBioMedicine · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications. PMID 42085320 · CPT Pharmacometrics Syst Pharmacol · 2026-May 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluating linaclotide for the treatment of functional constipation in children and adolescents. PMID 42083746 · Expert Opin Pharmacother · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. PMID 42080361 · Future Oncol · 2026-May This is an original, pre-specified exploratory analysis from a Phase III randomized trial (NAPOLI 3) in an oncology setting (metastatic pancreatic ductal adenocarcinoma) with a drug-containing intervention (NALIRIFOX vs. gemcitabine plus nab-paclitaxel). However, the report's primary focus and results are exclusively on safety/toxicity outcomes (treatment-emergent adverse events) stratified by a biomarker (UGT1A1*28 genotype). It does not report any formal time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) as required for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -